Health systems around the world would like to deliver personalised medicine for everyone, where providers are reimbursed for the patient outcomes they create and patients benefit from continuous improvement and safety. This rarely happens with current models of care.
In essence the feedback loop between patient and doctor needs to be tightened, and to include information on the effectiveness of the prescribed interventions, whether drug-based, behavioural, lifestyle or wellness advice.
The Closed Loop approach fully integrates the prescribed regimen so that the feedback from different interventions can be used to personalise care for the individual, providing a much faster way of getting an individual to their optimum outcome.
Closed Loop Medicine (CLM) is a new breed of therapeutics company focused on care pathways, outcomes and the provision of dynamic personalised regimens. The company combines proven drugs with digital therapeutics and, where relevant, devices and diagnostics, through a single prescription enabling the digitisation and data capture of an entire care continuum.
CLM has a pipeline of pathway interventions in development that integrate Digital + Drug + Device for the treatment of some of the biggest challenges facing 21st century health systems – sleep disorders, hypertension, chronic pain and diabetes.
IQ Capital invested in CLM at Seed stage in 2019.